ARTICLE | Clinical News

Copegus ribavirin regulatory update

September 27, 2010 7:00 AM UTC

The U.K.'s NICE issued guidance recommending the use of peginterferon alfa and ribavirin to treat chronic HCV infection in non-responding or relapsed adults after receiving the combination or peginterferon alone, or who are co-infected with HIV. The agency also recommended shortened courses of therapy for adults who have a rapid virological response after 4 weeks. The guidance, which is in line with an August final appraisal determination (FAD), updates 2004 and 2006 guidances on HCV treatments. ...